Based on the Impassion130 study, PD-L1 inhibitor atezolizumab combined with nab-paclitaxel has been approved in the first-line treatment of triple-negative breast cancer (TNBC) (4, 5), which opens up a new window for the treatment of advanced TNBC. The gene discussed is CD274; the disease is triple-negative breast carcinoma.